advanced follicular lymphoma

September 26, 2019

FDA Grants Abexinostat Fast Track Status for Follicular Lymphoma

News

Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

February 2, 2018February 2, 2018

Aggressive Treatment Seen to Help Advanced Follicular Lymphoma Patients in Phase 2 Trial

News

Sequential chemoimmunotherapy, radioimmunotherapy, and maintenance treatment with Rituxan (rituximab) improves progression-free survival and delays disease progression in patients with untreated advanced follicular lymphoma, Phase 2 clinical trial data shows. The study reporting ... Read more